Helus Pharma $HELP: HLP003 and the Phase 3 MDD Test

01 The business: what has to become true

Helus is attempting to build a pharmaceutical business around proprietary serotonergic compounds. Its economic value cannot be reduced to the size of the population experiencing depression or anxiety. A development-stage asset must pass several successive tests before a large clinical need becomes accessible revenue. The treatment must work in the proposed population, have a benefit-risk profile that supports authorization, be deliverable through an acceptable clinical workflow and receive payment on terms that make provision sustainable.

The lead depression thesis is specific. A patient already receives background pharmacotherapy, remains symptomatic and is treated intermittently with an additional investigational medicine. That model could offer a useful alternative if benefit persists between sessions. It also creates a demanding practical proposition: patients and clinicians would need sufficient confidence in the supervised intervention to accept its time commitment, preparation and follow-up requirements. The degree of benefit required for adoption may differ from the minimum needed to separate from placebo statistically.

From a business perspective, the distinction between a medicine and its delivery pathway is central. A capsule can be manufactured and distributed, but a supervised experience needs trained personnel, suitable facilities, scheduling and clinical oversight. Even with an approved product, adding treatment capacity could be slower than shipping additional units. Conversely, a well-designed pathway could improve consistency, patient confidence and referral behavior. These are conditional business implications of the proposed treatment model, not demonstrated commercial outcomes.

The company name change can make the portfolio easier to communicate, but scientific continuity matters more than branding. The same lead programs have appeared under earlier identifiers. HLP003 corresponds to CYB003, while HLP004 corresponds to CYB004 in the August 14 MD&A. Historical evidence belongs to those underlying compounds and study designs, regardless of which name appears on an older document. Rebranding creates no new efficacy observation.

For shareholders, successful development would transform an uncertain research asset into a better-defined future opportunity. However, that transformation has a cost and a denominator: future commercial value would belong to the then-outstanding equity holders, after additional financing and obligations. Analysis of the business therefore needs both clinical progress and capital discipline. A sophisticated scientific thesis can still create an unattractive economic outcome if delivery costs or dilution absorb too much of its value.

02 HLP003: a plausible mechanism needs outcome evidence

The company describes HLP003 as a proprietary deuterated serotonergic agonist targeting pathways that include the 5-HT2A receptor. Its program description identifies a new chemical entity with FDA Breakthrough Therapy Designation for adjunctive MDD. The September 2026 PARADIGM poster describes a deuterated psilocin analog. Those descriptions provide scientific and regulatory context, while the therapeutic proposition still depends on controlled outcomes.

Changing a molecule can change its pharmacological behavior. Whether that change produces a better medicine depends on the balance among exposure, subjective effects, therapeutic benefit and adverse events. An attractive explanation of receptor activity cannot answer how reliably patients improve, how long improvement lasts or which patients should avoid treatment. These are empirical questions, and the relevant experiment measures patients rather than the elegance of the molecular design.

The intermittent dosing concept also creates a useful distinction between pharmacological exposure and clinical durability. A compound need not remain at high concentrations for months for its clinical effects to persist. Equally, a short acute experience offers no assurance of a durable benefit. The hypothesis is interesting because those timescales could differ; evidence of durability must come from follow-up with appropriate information on intervening treatment and missing observations.

The adjunctive approach has a practical rationale. Removing a background antidepressant can introduce withdrawal effects, relapse risk and inconvenience. Continuing it can improve feasibility, but also makes the combined treatment the relevant object of evaluation. A result in that setting describes the investigated combination strategy. It should be interpreted in the population, background therapy and support environment actually studied, rather than expanded automatically into every form of depression.

The company’s August update reported a favorable pharmacokinetic drug-interaction study across six tested substrates. That is useful information for an adjunctive development strategy. However, an interaction assessment and a clinical benefit-risk assessment answer different questions. Limited effects on the metabolism of selected medicines do not by themselves settle psychiatric tolerability, all potential interactions or outcomes in medically complex populations. August 14 SEC-filed update.

Mechanistic enthusiasm becomes more valuable when it survives a disciplined clinical test. For HELP, the next meaningful change in scientific credibility should therefore be driven by the controlled result and the quality of the underlying dataset. A pharmacological narrative can explain why a study is worth doing; the study determines how much confidence that narrative deserves afterward.

03 APPROACH: how to read the pivotal result

APPROACH is designed to test an adjunctive regimen against inactive placebo. The August MD&A describes a planned two-dose schedule, administered three weeks apart, and a primary measure of MADRS change six weeks after the first dose. It records final enrollment of 223 participants, compared with an original plan of approximately 220. August 14 MD&A, HLP003 program section; ClinicalTrials.gov study NCT06564818.

The central number in the eventual readout is the difference between randomized groups, alongside its uncertainty. A large improvement within the active group can be encouraging without showing how much of that improvement is attributable to the investigational intervention. Trial participation, attention, expectations, background treatment and the natural variability of depressive symptoms can affect outcomes in both arms. The controlled comparison is intended to separate those shared influences from the additional effect of assignment to active treatment.

Statistical significance has a clear role but a limited scope. It addresses a formal null hypothesis under the prespecified analysis. It does not measure commercial attractiveness, identify every subgroup that benefits or establish that the exact observed effect will recur. The treatment difference, confidence interval and clinical context help describe the range of plausible benefit. A narrowly positive result with considerable uncertainty would carry different implications from a robust separation supported by other measures.

Consistency is also informative. If depression symptoms improve on the primary scale, supportive findings in response, remission or functioning could make the overall picture easier to interpret. Secondary endpoints still require their proper statistical context. A favorable isolated measure after an unsuccessful primary test is weaker evidence than a coherent result under a successful prespecified testing plan. Selecting whichever endpoint looks strongest after the event creates an overly flattering interpretation.

Safety belongs in the first reading of the release. Overall adverse events, serious events, discontinuations, psychiatric deterioration and relevant monitoring findings can change the meaning of a positive efficacy result. A treatment that helps some patients but creates a significant management burden may require a more restricted delivery model. The aggregate frequency of events is useful, while their severity, timing, reversibility and relationship to treatment are equally important.

Missing data deserve attention because a six-week result can be sensitive to who remains in observation and how unavailable scores are handled. An outcome driven by a narrow subgroup or particular assumption would deserve more caution than one supported across reasonable analyses. The appropriate response is to examine the prespecified analysis population and sensitivity results as they become available, without inventing a private statistical standard after seeing the headline.

Finally, the expected quarter is a window. Data collection, database cleaning and analysis take time after enrollment. ClinicalTrials.gov lists September 4, 2026 as the actual primary completion date for APPROACH. NCT06564818. A scheduled investor event may help explain the program, but it is not interchangeable with a results announcement. The clinical interpretation should begin with the actual study findings whenever they are released, not with a calendar-based assumption that management has already disclosed a positive outcome.

04 The early durability signal: impressive numbers, a small denominator

The early durability observation is unusually memorable and unusually easy to overextend. In the December 2024 ACNP poster, the long-term observational follow-up included 21 of 36 participants from the MDD cohorts. Seven had received two 16 mg doses. That subgroup had a roughly 23-point MADRS improvement from baseline at 12 months, with 100% response and 71% remission. The poster identifies the follow-up as non-interventional. Original poster.

Seven favorable patient experiences can be clinically meaningful to those individuals. They provide a much less stable estimate of the frequency of benefit in a broad population. A percentage close to a round headline can conceal the fact that a single person’s outcome changes the reported rate substantially. The denominator is therefore part of the result, rather than a technical footnote that can be detached from it.

The follow-up also asks a different question from a pivotal randomized comparison. It describes how a selected group was doing after treatment, while a controlled study tests a treatment difference under a defined design. Long observation is valuable, especially when the treatment is intermittent, but the passage of time alone does not create a comparison group. Background medications and other care can influence the observed trajectory after the controlled period has ended.

Attrition has to be interpreted carefully. The poster explains that non-enrollment in follow-up was not attributed to adverse events and that many non-participants had previously been in remission. That is relevant context, although it does not turn the observed subset into a complete population estimate. Both favorable and unfavorable outcomes among people without follow-up would affect any broader interpretation. Assuming they all failed would be as unjustified as assuming they all retained benefit.

Remission thresholds introduce another layer. A person near a cutoff can move between categories after a small score change, while their lived clinical condition changes little. Mean symptom change and categorical remission rates should therefore be considered together. Reclassifying patients with a different threshold can be illustrative, but it does not create a new outcome or improve the underlying precision of a tiny sample.

For the development thesis, the appropriate inference is that durability is plausible enough to investigate rigorously. The observation increases interest in extension data and repeat-treatment strategies. It provides no reliable basis for assuming that every treated patient in Phase 3 will respond or that long-term remission will reproduce at the same percentage. Larger randomized evidence and transparent longer-term follow-up have complementary roles in testing that proposition.

05 EMBRACE and EXTEND: replication and durability are different jobs

The second pivotal study, EMBRACE, is a three-arm comparison of two active doses and placebo. The UK Health Research Authority describes approximately 330 planned participants, with 8 mg, 16 mg and placebo groups and doses on Day 1 and Day 22. Its public summary links the study to NCT06793397. HRA summary, favorable opinion dated June 30, 2025.

A second study can add confidence by testing whether a signal survives changes in patients, sites and ordinary trial variability. Reproducibility matters because a single study may overestimate or underestimate the underlying effect. The additional dose arm also creates an opportunity to understand whether a lower dose preserves useful benefit or changes tolerability. Such a result could matter for the future treatment model, although any final dosing strategy would depend on the complete program and regulatory review.

An apparently inconsistent dose-response pattern would need careful interpretation. Psychiatric symptom endpoints contain variability, and modest sample sizes can make neighboring dose groups appear more different than their underlying effects. Conversely, similarity across doses could reflect a genuinely broad active range. The correct interpretation depends on the estimates, uncertainty and prespecified comparisons, rather than a simple expectation that every higher dose must produce a better score.

EXTEND is the longer-term extension within PARADIGM. The company describes open-label treatment or retreatment for eligible nonresponders and participants who relapse. HLP003 program description; ClinicalTrials.gov NCT06605105. That creates the possibility of learning how a practical intermittent regimen might work beyond the initial treatment period.

Retreatment data could clarify whether a returning symptom burden can be improved again and how often additional intervention is needed. From a commercial perspective, that frequency influences clinic capacity, patient inconvenience and annual treatment cost. From a medical perspective, cumulative exposure and safety over repeated sessions matter. These questions cannot be settled by simply extending an initial short-term efficacy curve into the future.

Open-label evidence has limits because participants and investigators know the intervention. Its value lies in the information it can contribute about experience over time, patterns of recurrence and additional exposure. A strong extension trajectory would be supportive, but it would not substitute for a convincing randomized treatment difference. Each element of the program is more useful when it is allowed to answer the question it was designed to address.

06 What the broader literature adds, and where read-through stops

The wider psilocybin literature gives the HELP story useful context. Raison and colleagues reported a randomized MDD trial in JAMA in 2023 with 104 participants, using psilocybin with psychological support against niacin. The published study reported an antidepressant benefit on the primary MADRS outcome. Participants taking relevant psychotropic medication underwent tapering before treatment. Raison et al., JAMA, DOI 10.1001/jama.2023.14530.

A contrasting example is the 2026 EPISODE trial, reported by Mertens and colleagues in JAMA Psychiatry. It randomized 144 participants with treatment-resistant depression and did not meet its primary response endpoint. Exploratory symptom changes were more encouraging, while adverse reactions also required attention. Mertens et al., DOI 10.1001/jamapsychiatry.2026.0132. These are studies of another compound and different populations, rather than HLP003 trials.

The distinctive lesson is the difference between a general therapeutic hypothesis and a specific successful development program. Research can support the plausibility of an approach while producing mixed outcomes across individual trials. An effective molecule in one population, dose regimen and support setting does not guarantee an effective result elsewhere. Likewise, a disappointing trial elsewhere does not determine HLP003’s outcome. Class-level evidence can inform the questions without supplying the answer.

This is particularly relevant to adjunctive development. A study requiring medication tapering and a study continuing background antidepressants do not investigate identical treatment conditions. Continuing treatment may be practical, but it can also change the patient population and pharmacological context. The correct comparison is therefore conceptual: what design features improve interpretability and what evidence is still needed? Ranking headline effect sizes across unrelated studies would invite false precision.

Functional masking is another important question. A pronounced subjective experience can help participants infer assignment, even if capsules look identical and formal procedures remain blinded. Expectations may then affect reporting or behavior. That does not imply that all observed benefit is artificial; it means the experiment must work harder to separate the treatment effect from the consequences of knowing or guessing the treatment experience.

The FDA’s July 2026 final guidance on psychedelic clinical investigations addresses challenges in this field and finalizes the draft issued in June 2023. FDA guidance page. The guidance provides nonbinding recommendations; it is not a product-specific approval decision. For HELP, strong clinical evidence would be especially persuasive if the results remain coherent despite the acknowledged difficulty of masking the acute experience.

Long-term observations also need their own evidentiary discipline. A durable trajectory is more compelling when follow-up is complete, intervening care is described and the analysis acknowledges which questions remain uncontrolled. The clinically important idea is durable improvement. The methodological challenge is deciding how confidently that improvement can be attributed to the investigated strategy. Both deserve equal space when interpreting a breakthrough-oriented development thesis.

07 HLP004: optionality with a different evidentiary burden

HLP004 is the company’s investigational deuterated DMT-related program for generalized anxiety disorder. The March 5, 2026 release describes 36 patients, with a 20 mg arm and a 2 mg low-dose arm, receiving intramuscular administration. The high-dose group showed a 10.4-point HAM-A reduction from baseline at six weeks, with p<0.0001 for the within-subject change. The low-dose group also experienced subjective effects and clinical improvement. Original HLP004 topline announcement.

The comparison distinction is material. A very small p-value for change from baseline can coexist with uncertainty about how much better a high dose performs than its comparator. When both groups receive an experience capable of affecting expectations and symptoms, the trial has to characterize that comparison explicitly. Interpreting an internally significant change as proven superiority would inflate what the experiment shows.

The lower-dose experience is scientifically informative in its own right. It may help explain dose selection, control selection and the need to characterize the acute subjective response. However, a dose that is too biologically or psychologically active to function as a clean comparator can complicate the apparent treatment difference. A useful next study would need a design that can discriminate among these explanations rather than merely repeat favorable changes within each group.

The proposed short-acting profile could matter for clinic workflow. Shorter acute effects may allow more flexible scheduling and reduce the duration of intensive observation. Real discharge readiness still depends on the complete patient assessment and clinical setting. A shorter pharmacological experience alone would not determine the required staffing, monitoring or appropriate safeguards. The business benefit would have to be demonstrated through a reliable delivery model.

For portfolio analysis, HLP004 contributes scientific optionality without diversifying away every risk in HLP003. Both programs involve serotonergic medicines, psychiatric endpoints and supervised administration questions. They may share capabilities and useful operational learning, but also share parts of the regulatory and financing burden. Two programs can therefore be more valuable than one without providing the independence normally associated with unrelated revenue streams.

In August 2026 the company said it intended to complete the design of the next HLP004 study by the end of the third quarter of 2026; as of October 16, 2026, it had not announced the completed design or the start of that study. A design milestone and a successful therapeutic result sit at different points in that sequence. For HELP, HLP004 is therefore an earlier development opportunity whose future contribution depends on additional clinical evidence.

Behind the two clinical programs sits HLP005, formerly CYB005, a preclinical program of phenethylamine and tryptamine derivatives. The August MD&A describes several compounds being studied in vitro and in vivo to select development candidates, and the June-quarter release says the company anticipates a viable development candidate in the second half of 2027. Candidate selection would be a research milestone: it would not be a clinical trial under way, efficacy data in patients or a source of revenue. August 14 MD&A, HLP005 program; June-quarter financial release.

08 Cash, burn and the distance to a commercial business

The June-quarter financial release reported US$47.8 million net loss, US$37.5 million cash-based operating expenses and US$37.1 million operating cash used. These figures describe different accounting measures. The cash balance at the period end was US$166.4 million. All refer to the quarter ended June 30, 2026, with results published August 14. SEC-filed financial release.

Dividing that reported cash balance by that quarter’s operating cash use produces approximately 4.5 quarters, or 13.5 months, of equivalent expenditure. This is a simple arithmetic illustration using historical figures, not company runway guidance and not a current cash estimate. It assumes a constant spending rate and ignores changes in working capital, financing, investment and program intensity. In a development company, those assumptions can be materially wrong.

The distinction matters because a positive pivotal result can increase spending opportunities. An organization may need more manufacturing work, regulatory preparation, additional studies or commercial planning precisely when its scientific prospects improve. A higher expected program value can justify that spending while shortening the period before another financing. Conversely, reprioritizing programs can reduce outflow while sacrificing optionality or slowing development. Cash is a strategic resource, not simply a countdown clock.

Net loss is not a substitute for operating cash flow. Equity-based compensation, valuation adjustments and other noncash entries can affect loss without consuming the same amount of cash during the period. Operating cash flow can in turn be affected by payment timing, accrued expenses and working capital. Neither measure should be discarded: the first describes financial performance under the accounting framework, while the second helps explain how cash moved through operations.

The June quarter shows how the two measures connect. Total expenses of US$49.082 million comprised US$30.761 million of research, US$6.747 million of general and administrative costs and US$11.574 million of share-based compensation; after US$1.282 million of interest income and a small foreign exchange loss, the net loss was US$47.819 million. Removing noncash items — US$11.574 million of share-based compensation, a US$0.019 million foreign exchange loss and US$0.031 million of depreciation and amortization — and adding a US$0.875 million increase in working capital brings the figure to the US$37.070 million of operating cash used. Net financing inflow of US$46.533 million, mainly from the June offering, is already included in the US$166.365 million period-end cash balance, so it should not be added to that balance a second time. August 14 MD&A, results of operations and cash flows.

A useful financial assessment asks what obligations and milestones lie between the balance sheet date and the point at which the business could finance itself. Clinical results, regulatory submission, review and launch form separate stages. Cash sufficient to generate a key result can materially improve strategic flexibility, but it is a narrower achievement than financing every stage through commercialization. The appropriate funding comparison depends on the actual remaining work.

The June financing illustrates why capital and evidence should be considered together. Raising money before a binary event can reduce financial vulnerability if the result disappoints. It can also create dilution before an outcome that might have supported better terms. Management cannot know that future outcome with certainty. The decision therefore involves exchanging some per-share upside for additional operational resilience. Whether the exchange proves effective depends on the evidence generated and subsequent capital requirements.

For HELP, the first readout could change the cost and availability of capital in either direction. Strong data may widen financing and partnership options; ambiguous data may prolong spending while leaving valuation difficult; unfavorable data may restrict access and force reprioritization. These are conditional economic relationships, not predictions about the timing or structure of a future transaction. The published cash figure remains historical until a later financial disclosure replaces it.

09 Dilution: the share denominator deserves its own chapter

The June 25, 2026 common-share offering issued 10,309,280 shares at US$4.85, raising US$50 million gross. The release reported US$3 million underwriting commission, before other offering costs. The August MD&A adds US$467,000 of professional fees as share issuance costs, which leaves net proceeds of about US$46.5 million. MD&A, June 2026 offering. Those proceeds support development and general purposes. Closing announcement filed with SEC.

The August MD&A shows 73,060,172 common shares outstanding at its August 14, 2026 date. It also lists 12,016,335 ordinary purchase warrants, 1,111,967 options, 1,645,678 RSUs and 425,000 PSUs. The same document describes 7,889,846 shares issued on July 1 upon RSU vesting. MD&A, outstanding share data and subsequent events.

The move from quarter end to the MD&A date can be traced step by step: 61,984,078 shares at June 30, plus 7,889,846 issued on July 1 upon RSU vesting, plus 2,997,248 issued on August 10 on exercise of all 2,997,253 pre-funded warrants, plus 189,000 issued the same day on exercise of ordinary warrants, equals the 73,060,172 reported on August 14. Separately from the awards already outstanding, the company had a contractual obligation, which crystallized on August 10, 2026, to grant 509,798 additional RSUs to certain officers. Those units are not part of the 1,645,678 outstanding RSUs, and adding every listed instrument together would not produce an official fully diluted count, because vesting, exercise and performance conditions differ. MD&A, restricted share units and subsequent events.

These are different instruments and should be interpreted separately. An option or ordinary warrant generally requires exercise and can bring cash if exercised. A restricted share unit can add shares as it vests without the same cash inflow. A performance award depends on its specified conditions. An unissued award is not already an outstanding common share, while its existence can still matter for the future participation of current holders.

The distinction between pre-funded and ordinary warrants is also important. A pre-funded instrument typically reflects capital received largely in advance, with only a nominal residual exercise payment. Moving it into common shares can change the reported basic count without providing a meaningful new pool of cash. Adding all warrant categories to the business’s funding resources would therefore be misleading. The relevant treatment follows the actual instrument terms and its status on the specified date.

The share count can change materially between quarter end and the publication of that quarter’s results. A valuation built from an older basic count can overstate the ownership represented by each share. Around a financing or large vesting event, quarter-end figures and subsequent-event figures need to remain distinct. The financial statement date alone is not sufficient to identify the most relevant denominator.

Financing capacity is different from completed issuance. The MD&A describes a US$100 million 2026 ATM program and states that no shares had been sold under it as of June 30, 2026. MD&A, ATM section. An available mechanism expands management’s options while creating potential future supply; neither fact proves a specific upcoming sale.

The economic test of dilution is more demanding than whether the share count increased. Capital that enables a convincing experiment can create value, even when existing holders own a smaller percentage afterward. Repeated issuance without sufficient progress can have the opposite effect. A careful assessment therefore tracks the relationship between added claims, added cash and added evidence. The number of programs announced is less informative than the evidence delivered per unit of capital consumed.

10 Ownership, incentives and governance

Ownership influences governance and trading dynamics, but a name on an ownership list is not clinical validation. Large holders can have different entry prices, liquidity needs, investment horizons and portfolio constraints. Their disclosed position also reflects a past reporting date. Treating an institutional filing as a current endorsement of every subsequent development would give it more meaning than it carries.

In August and September 2026 several executives reported open-market purchases on Form 4. Executive Chair Eric So bought 295,000 shares between September 1 and September 8 at about US$11.81–12.39. Chief Growth Officer Paul Glavine bought 290,000 shares between August 31 and September 8 at about US$11.59–12.47. CEO Michael Halstead bought 100,000 shares on September 21 at about US$13.47, and CFO Greg Cavers bought 3,000 shares on September 29 at US$12.91. Schedule 13D filings dated September 9 show Eric So and Paul Glavine each at about 5.8% beneficial ownership, including shares received through equity awards; both also reported awards of 248,000 shares on September 30. Insider purchases signal management’s own commitment; they are not clinical evidence. Form 4, So, Sept. 1 · Sept. 4 · Sept. 8 · Form 4, Glavine, Aug. 31 · Sept. 3 · Sept. 8 · Form 4, Halstead · Form 4, Cavers · Schedule 13D · Schedule 13D.

For HELP, the documented equity instruments and July vesting event are directly relevant to incentives. Awards can help recruit and retain experienced personnel, particularly at an important development stage. They also impose an economic cost through additional claims on the business. The governance question is whether compensation rewards durable progress and appropriately accounts for the capital required to reach it.

Share-price-linked incentives have a different character from purely clinical or operational milestones. A rising market price may reflect improved expected value, broader sector enthusiasm or temporary event positioning. It can be a useful incentive, but it is not interchangeable with a successful trial or an efficient regulatory plan. A balanced assessment considers whether management’s rewards align with the quality and persistence of progress, rather than a short-lived market reaction.

Michael Halstead became CEO on August 3, 2026. The company identified him as the former president of Intra-Cellular Therapies, with late-stage development and commercialization experience. Eric So was described as co-founder and executive chairman. SEC-filed appointment announcement. Relevant experience can improve the quality of planning and execution; it cannot determine the outcome of a blinded experiment.

The October 15 Durgam board announcement adds another executive with CNS development experience, subject to the exchange approval condition stated in the release. Original company announcement. The connection between leadership backgrounds and the company’s clinical area is sensible. It is still a governance development, rather than a clinical data release or a transaction signal.

The strongest evidence of governance quality will accumulate through decisions: realistic guidance, transparent reporting of difficult findings, disciplined capital allocation and clear distinction between demonstrated results and ambitions. A management team can earn credibility by explaining limitations as clearly as favorable observations. That quality becomes especially important when an unusually memorable early headline creates expectations that a larger study may have difficulty matching.

11 Regulation: designation, submission and approval

Breakthrough Therapy Designation is relevant because it signals an opportunity for closer regulatory engagement around a serious condition and preliminary clinical evidence. It does not eliminate the need for persuasive efficacy and safety data. The FDA’s description of the program explains that the designation supports development; it is not marketing authorization.

A positive first pivotal trial would represent progress within the evidence package. Regulators would still evaluate the broader program, including corroborating evidence, the safety database, dosing, manufacturing and the proposed use conditions. The final label can be narrower than the commercial narrative used during development. It may define which patients are eligible, how treatment is administered and what monitoring is necessary.

Manufacturing is part of the regulatory proposition because the medicine delivered to patients must meet appropriate quality requirements consistently. Reliable clinical outcomes are less commercially useful if the product cannot be manufactured, controlled and supplied as required. For a novel compound, process development and quality work can continue well after the scientific concept has become widely understood. These activities consume time and resources without necessarily generating dramatic news headlines.

The treatment environment also matters. Supervision, patient selection and observation can contribute to benefit-risk management. A regulator’s requirements can affect capacity and economics even if the molecular product is approved. Commercial planning therefore needs to accommodate plausible restrictions rather than assume that every element of the trial setting will disappear after authorization.

Helus referred to a potential U.S. NDA in 2028 in its July 21, 2026 release. Enrollment announcement. That is a forward-looking development objective, conditional on successful execution and results. It is not an FDA decision date, a guaranteed submission year or an approval promise.

For an event-focused reader, this creates several distinct milestones: the first result, further pivotal evidence, longer safety observation, completion of the submission package, submission, acceptance for review and the eventual regulatory decision. Each can change uncertainty in a different way. Combining them into a single idea of being near approval would obscure both the remaining work and the financing needed to complete it.

12 Competition and commercialization: winning a trial is only the beginning

The commercial comparison is broader than other psychedelic compounds. A patient with depression may have access to established medicines, psychological treatment and other interventions through an existing care pathway. A new approach would compete for clinician confidence, patient time, payer resources and treatment capacity. The size of the unmet need helps explain why the opportunity matters; it cannot determine the portion a particular intervention could serve economically.

A supervised intermittent treatment could have attractions if benefit is sufficiently reliable and durable. Patients may value an alternative to adding another daily medicine. Clinicians may value a response in people who remain symptomatic. Payers may value better functioning or reduced downstream care. Each potential advantage needs evidence and a workable operational model. A theoretical reduction in treatment frequency is less useful if the total pathway remains difficult to access.

Clinic capacity is a practical constraint in this scenario. A facility must have suitable staff, observation space and schedules that accommodate treatment and recovery. Patients may need transport and time away from work or family responsibilities. These demands can affect uptake independently of efficacy. A meaningful commercial forecast would therefore require more than multiplying a population estimate by a proposed medicine price.

Reimbursement introduces another layer. Payment for the drug and payment for clinical services may involve different participants and incentives. A provider may support the medical concept while hesitating to expand capacity if the reimbursement pathway is uncertain. A payer may accept the evidence of benefit while requiring prior treatment failures or other eligibility conditions. The eventual adoption curve would reflect these decisions alongside the approved indication.

Durability and retreatment frequency connect the clinical and economic questions. Longer benefit could reduce the frequency of expensive supervised sessions and improve convenience. More frequent retreatment might still be clinically worthwhile but change annual costs and capacity requirements. The commercial relevance of extension data therefore extends beyond a favorable symptom curve: it helps define how often the service must be delivered.

Competition also evolves while a program advances. A successful rival can validate interest in a mechanism and create a treatment infrastructure. It can simultaneously establish a more demanding efficacy, safety or convenience benchmark. Commercial planning should remain conditional on the alternatives available at launch. An early data advantage is valuable only if it translates into a differentiated proposition when real treatment choices are made.

13 Scenarios and the facts that would weaken them

A convincing first pivotal result. In the constructive clinical scenario, the primary endpoint favors HLP003 with a clear treatment difference, uncertainty is reasonably contained, supportive measures point in the same direction and safety remains manageable. That would strengthen confidence in continued development. It would still leave replication, longer observation, regulatory review and commercialization. Evidence that undermined this scenario would include a fragile analysis, important unexplained discontinuations or a safety finding that changed the practical benefit-risk balance.

A positive but commercially difficult result. Statistical success could coexist with a modest treatment difference, high delivery burden or a subgroup pattern that narrows applicability. The program might remain viable while expectations require adjustment. This scenario would become more credible if the treatment burden appeared large relative to the additional benefit. Conversely, consistent improvements in functioning and a manageable operational model would strengthen the argument that the result matters beyond its p-value.

An ambiguous result. A dataset could contain favorable observations without supporting an uncomplicated success conclusion. Missing the primary endpoint while showing encouraging exploratory measures would create a different financing and development problem from a clean primary success. The next questions would be whether the findings are reproducible, whether a defensible revised study can answer the uncertainty and how much capital that study would consume. Reinterpreting an unsuccessful endpoint after the event would not resolve the uncertainty.

An unfavorable result. Little separation from placebo or a material safety problem would weaken the core near-term thesis. Cash could preserve strategic options, including reprioritizing the earlier pipeline, but those options would have their own timelines and evidence requirements. The existence of another program cannot automatically replace the value attributed to the lead one. The falsifier of a pessimistic interpretation would be new persuasive controlled evidence, rather than a change in corporate messaging alone.

A timing change. A delay may be operational, analytical or clinical, and its meaning depends on the explanation. A later release date does not logically show either efficacy or failure. It can still matter financially because time consumes resources and affects the sequence of funding decisions. A transparent explanation and a specific revised plan would reduce one form of uncertainty; the eventual dataset would answer the clinical question.

Market reactions depend on prior expectations, positioning, available liquidity and the details of the result. The clinical and economic analysis should remain anchored to what changed in the evidence and what remains to be funded. That discipline is most useful when a dramatic headline encourages a faster conclusion than the dataset can support.

14 A practical framework for following the readout

The first useful distinction is among event types. A governance announcement changes leadership oversight. A financing changes resources and claims on the business. A trial update changes operational visibility. A controlled data release changes the clinical evidence. These developments can interact, but treating them as equivalent sources of clinical validation invites mistakes.

Some market commentators have raised questions of method about APPROACH: the strength of the placebo comparison, the durability of any benefit, whether blinding can hold, and the capital the program will need. These are opinions about what the data must show, not findings. They match the uncertainties discussed in the earlier chapters, and the published results will be the test.

For the pivotal result, the sequence of interpretation can remain simple. Start with the prespecified primary outcome and comparison. Consider the size and uncertainty of the treatment difference. Look for consistency in supportive measures and examine whether the reported analysis includes the intended population. Then assess safety and discontinuations alongside efficacy. Only after that does it make sense to discuss how the findings might alter the remaining development plan.

The next layer is the commercial significance of the observed profile. A result can be biologically interesting without offering a clear advantage in routine care. Questions about patient selection, duration, repeat treatment and delivery help translate efficacy into a proposed use case. This translation remains conditional until additional evidence and a regulatory label define it more fully.

The financial layer should then be updated using the most relevant reported dates. Cash at a prior quarter end, shares at a later filing date and an immediately current stock price represent different moments. Combining them without explanation can make a valuation look precise while introducing a material denominator error. A plausible narrative does not repair inconsistent inputs.

Finally, future company guidance should be kept separate from completed events. A planned filing year is a target. An announced study design is a plan for generating evidence. A completed trial is an operational achievement. A favorable result is a measured outcome. An authorization is a regulatory decision. Maintaining these distinctions allows the HELP thesis to change as evidence changes, without repeatedly rebuilding the story around whichever headline appears most encouraging.

15 Sources and frequently asked questions

Principal sources

1. Helus Pharma, October 15, 2026 board appointment.
2. Helus Pharma, October 8, 2026 investor presentation announcement.
3. Helus Pharma, October 1, 2026 legal name change.
4. Helus Pharma, August 14, 2026 financial results filed with SEC and MD&A.
5. Helus Pharma, August 3, 2026 CEO appointment.
6. Helus Pharma, July 21, 2026 APPROACH enrollment completion.
7. Helus Pharma, June 25, 2026 offering close.
8. Helus Pharma, March 5, 2026 HLP004 results.
9. Inamdar et al., ACNP December 2024 CYB003 long-term follow-up poster.
10. UK HRA, EMBRACE research summary; ClinicalTrials.gov APPROACH, EMBRACE, EXTEND.
11. Raison et al., 2023, JAMA, Single-Dose Psilocybin Treatment for Major Depressive Disorder, DOI 10.1001/jama.2023.14530.
12. Mertens et al., 2026, JAMA Psychiatry, Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial, DOI 10.1001/jamapsychiatry.2026.0132.
13. FDA, Psychedelic Drugs: Considerations for Clinical Investigations, July 2026 final guidance, and Breakthrough Therapy explanation.

Is HELP the former Cybin?

Yes. The company adopted the Helus Pharma business name and HELP trading symbol, and its legal name became Helus Pharma Inc. on October 1, 2026. Older trial materials may use Cybin and the CYB003 or CYB004 program identifiers. The renaming preserves continuity of the underlying programs.

Is the October 21 presentation the Phase 3 readout?

The presentation announcement identifies a discussion of the development programs and clinical landscape. The published APPROACH topline guidance is Q4 2026. The meeting announcement does not specify that the results will be released at that event.

Does the early response rate predict Phase 3?

It offers a reason for interest, with a very small denominator and an observational follow-up design. The pivotal randomized treatment difference is the more important test of efficacy. The detailed limitations are discussed in Chapter 04.

Does Breakthrough Therapy Designation mean HLP003 is approved?

No. The designation can support development and regulatory interaction. Marketing authorization requires the evidence package and the regulator’s benefit-risk decision. HLP003 remains investigational.

Did HLP004 prove superiority to placebo?

The cited statistically significant HAM-A result is a change from baseline in a small signal-detection study. That comparison is different from demonstrated superiority between randomized treatment groups. The lower-dose arm also showed subjective and clinical effects.

Why can dilution remain relevant after good data?

Additional studies, manufacturing, regulatory preparation and commercialization can require resources. Good data may improve financing options while leaving those costs intact. Future value per share depends on both program progress and the equity claims outstanding when that value is realized.

What would most change the HELP thesis?

A convincing controlled efficacy result with an acceptable safety profile would strengthen the development case. A weak primary result, important tolerability problem or a substantially more expensive path would weaken it. Additional pivotal and longer-term data would refine either interpretation.

This analysis is prepared with AI assistance and reviewed against the linked sources. Interpretations and scenarios are editorial commentary; company timelines remain forward-looking. The content is educational and informational, not financial or medical advice and not an investment recommendation. Readers should verify information independently and consult appropriately qualified financial or medical professionals for decisions relevant to their circumstances.